Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk

被引:44
|
作者
Chatterjee, Ranee [1 ]
Narayan, K. M. Venkat [2 ,3 ]
Lipscomb, Joseph [4 ,5 ]
Jackson, Sandra L. [6 ]
Long, Qi [7 ]
Zhu, Ming [7 ]
Phillips, Lawrence S. [2 ,5 ,8 ]
机构
[1] Duke Univ, Sch Med, Dept Gen Internal Med, Durham, NC 27708 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA
[4] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA
[5] Atlanta VA Med Ctr, Decatur, GA USA
[6] Emory Univ, Grad Div Biol & Biomed Sci, Nutr & Hlth Sci Program, Atlanta, GA 30322 USA
[7] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA
[8] Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Atlanta, GA USA
基金
美国国家卫生研究院;
关键词
LIFE-STYLE INTERVENTION; GLUCOSE; PREVENTION; MELLITUS; ADULTS;
D O I
10.2337/dc12-1752
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-Although screening for diabetes and prediabetes is recommended, it is not clear how best or whom to screen. We therefore compared the economics of screening according to baseline risk. RESEARCH DESIGN AND METHODS-Five screening tests were performed in 1,573 adults without known diabetes random plasma/capillary glucose, plasma/capillary glucose 1 h after 50-g oral glucose (any time, without previous fast, plasma glucose 1 h after a 50-g oral glucose challenge [GCTpl]/capillary glucose 1 h after a 50-g oral glucose challenge [GCTcap]), and AlC-and a definitive 75-g oral glucose tolerance test. Costs of screening included the following: costs of testing (screen plus oral glucose tolerance test, if screen is positive); costs for false-negative results; and costs of treatment of true-positive results with metformin, all over the course of 3 years. We compared costs for no screening, screening everyone for diabetes or high-risk prediabetes, and screening those with risk factors based on age, BMI, blood pressure, waist circumference, lipids, or family history of diabetes. RESULTS-Compared with no screening, cost-savings would be obtained largely from screening those at higher risk, including those with BMI >35 kg/m(2), systolic blood pressure >= 130 mmHg, or age >55 years, with differences of up to -46% of health system costs for screening for diabetes and -21% for screening for dysglycemia(110), respectively (all P < 0.01). GCTpl would be the least expensive screening test for most high-risk groups for this population over the course of 3 years. CONCLUSIONS-From a health economics perspective, screening for diabetes and high-risk prediabetes should target patients at higher risk, particularly those with BMI >35 kg/m(2), systolic blood pressure >= 130 mmHg, or age >55 years, for whom screening can be most cost-saving. GCTpl is generally the least expensive test in high-risk groups and should be considered for routine use as an opportunistic screen in these groups.
引用
收藏
页码:1981 / 1987
页数:7
相关论文
共 50 条
  • [1] Screening for Prediabetes and Diabetes May Be Cost-Saving
    Chatterjee, Ranee
    Narayan, Km Venkat
    Lipscomb, Joseph
    Phillips, Lawrence S.
    DIABETES, 2009, 58 : A44 - A44
  • [2] Screening Adults for Pre-Diabetes and Diabetes May Be Cost-Saving
    Chatterjee, Ranee
    Narayan, K. M. Vencat
    Lipscomb, Joseph
    Phillips, Lawrence S.
    DIABETES CARE, 2010, 33 (07) : 1484 - 1490
  • [3] Screening Colonoscopy in Germany Is Cost-Saving
    Sieg, Andreas
    Brenner, Hermann
    GASTROINTESTINAL ENDOSCOPY, 2006, 63 (05) : AB207 - AB207
  • [4] Cost-saving HIV policy should be reviewed
    Westmore, A
    SEARCH, 1996, 27 (08): : 230 - 230
  • [5] Cost-saving analysis of screening colonoscopy in Germany
    Sieg, A.
    Brenner, H.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2007, 45 (09): : 945 - 951
  • [6] The paradox of scored tablets: a cost-saving risk
    De Spiegeleer, B.
    Van Hoorebeke, L.
    De Spiegeleer, A.
    Castelein, P.
    Van Bortel, L.
    PHARMAZIE, 2009, 64 (08): : 550 - 552
  • [7] Endoscopic colorectal cancer screening: a cost-saving analysis
    Loeve, F
    Brown, ML
    Boer, R
    van Ballegooijen, M
    van Oortmarssen, GJ
    Habbema, JDF
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (07) : 557 - 563
  • [8] Systematic Screening for Type 2 Diabetes (T2DM) in Thailand Is Cost-Saving
    Srinonprasert, Varalak
    Kingkaew, Pritaporn
    Kamol, Apiradee Sriwijit
    Teerawattananon, Yot
    DIABETES, 2014, 63 : A308 - A308
  • [9] Determining cost-saving risk thresholds for statin use
    Gandjour, Afschin
    PLOS ONE, 2025, 20 (03):
  • [10] Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving
    Prusa, Andrea-Romana
    Kasper, David C.
    Sawers, Larry
    Walter, Evelyn
    Hayde, Michael
    Stillwaggon, Eileen
    PLOS NEGLECTED TROPICAL DISEASES, 2017, 11 (07):